DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE Drug Patent Profile

When do Diphenhydramine Hydrochloride Preservative Free patents expire, and what generic alternatives are available?

Diphenhydramine Hydrochloride Preservative Free is a drug marketed by Abraxis Pharm, Dr Reddys, Fresenius Kabi Usa, and Intl Medication. and is included in four NDAs.

The generic ingredient in DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE is diphenhydramine hydrochloride. There are twenty-three drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the diphenhydramine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Diphenhydramine Hydrochloride Preservative Free

A generic version of DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE was approved as diphenhydramine hydrochloride by WEST-WARD PHARMS INT on December 31^st, 1969.

Summary for DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

US Patents:	0
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	115
Clinical Trials:	2
Patent Applications:	2,400
DailyMed Link:	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE at DailyMed

Recent Clinical Trials for DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stamford Anesthesiology Services, PC	N/A
I-Flow	N/A
Genentech, Inc.	Phase 2

See all DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE clinical trials

Pharmacology for DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

Drug Class	Histamine-1 Receptor Antagonist
Mechanism of Action	Histamine H1 Receptor Antagonists

US Patents and Regulatory Information for DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abraxis Pharm	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	080586-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Intl Medication	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	084094-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Dr Reddys	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	080873-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Fresenius Kabi Usa	DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE	diphenhydramine hydrochloride	INJECTABLE;INJECTION	091526-001	Mar 26, 2013	AP	RX	No	No

Market Dynamics and Financial Trajectory for Diphenhydramine Hydrochloride Preservative-Free

Last updated: March 6, 2026

What is the current demand and supply landscape for preservative-free diphenhydramine hydrochloride?

Demand for preservative-free formulations of diphenhydramine hydrochloride is growing. This trend aligns with increased awareness of preservative-related adverse reactions, especially in sensitive populations such as infants, elderly, and immunocompromised patients. The global antihistamine market was valued at approximately $1.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% from 2023 to 2030.[1]

Supply is concentrated among major generic pharmaceutical manufacturers, with key players including Johnson & Johnson, Mylan, and Dr. Reddy's Laboratories. The production process requires specific sterile and preservative-free manufacturing capabilities, leading to higher operational costs and potential supply constraints.

How does regulatory environment influence market access and pricing?

Regulatory agencies such as the U.S. Food and Drug Administration (FDA) impose strict standards for preservative-free injectable drugs, including stability, sterility, and packaging requirements. The FDA's Guidance for Industry on preservative-free formulations emphasizes rigorous testing to ensure safety and efficacy, which can extend approval timelines.[2]

Pricing strategies are influenced by regulatory oversight, high manufacturing costs, and market demand. Preservative-free formulations tend to command higher prices due to the complex manufacturing process and the perceived safety benefits. However, reimbursement rates depend on national policies and insurance coverage, varying significantly across regions.

What are the driving factors behind market growth?

1. Patient safety concerns: Aes the focus on minimizing adverse effects associated with preservatives such as benzyl alcohol and parabens.
2. Regulatory push: Governments and health authorities favor preservative-free options, especially for pediatric and geriatric use.
3. Technological advancements: Improvements in sterile manufacturing and packaging reduce costs and expand availability.
4. Clinical evidence: Studies indicate lower hypersensitivity reactions with preservative-free formulations.

Market penetration remains limited primarily to hospital settings and specialized clinics due to the higher cost compared to preservative-containing formulations.

What are potential barriers to market expansion?

• Manufacturing complexity increases production costs.
• Limited patient awareness might restrict demand in outpatient pharmacies.
• Existing patents or exclusivity rights on certain formulations can delay generic adoption.
• Regulatory delays can hinder product launch timelines.

How are pharmaceutical companies positioning themselves?

Companies are investing in R&D to develop stable, preservative-free formulations with extended shelf life. Strategic partnerships, acquisitions, and licensing agreements aim to accelerate market entry. Patent filings increased post-2020, focusing on novel delivery systems such as pre-filled syringes and single-dose vials.

What is the financial outlook for future investments?

Based on current trends:

Year	Market Size (USD billion)	CAGR	Key Growth Drivers
2022	0.09	-	N/A
2025	0.12	4.2%	Safety concerns, regulatory support
2030	0.17	4.2%	Increased adoption, technological innovation

The incremental revenue opportunities are driven predominantly by hospital procurement and niche markets where safety is prioritized.

What is the competitive landscape?

Leading players in the preservative-free antihistamine market include:

• Johnson & Johnson (McNeil Consumer Healthcare)
• Mylan (part of Viatris)
• Dr. Reddy's Laboratories
• Teva Pharmaceuticals
• Sandoz

Market share is fragmented, with no single entity dominating. Innovation in delivery systems and manufacturing efficiencies are critical for gaining competitive advantages.

Summary: Key Opportunities and Risks

• Opportunity to capture niche markets emphasizing safety.
• Rising demand for preservative-free formulations in pediatric and sensitive populations.
• Barriers include high manufacturing costs and regulatory hurdles.
• Market growth depends on technological advancements, reimbursement policies, and clinician prescribing behaviors.

Key Takeaways

• The preservative-free diphenhydramine hydrochloride market is small but expanding, driven by safety concerns and regulatory trends.
• High production costs and regulatory complexity are key barriers.
• Growth relies on technological advancements and strategic industry collaborations.
• Market access varies geographically, with developed regions leading demand.
• Future revenues are forecasted to increase at a CAGR of approximately 4.2% through 2030.

FAQs

What are the advantages of preservative-free diphenhydramine formulations?
They reduce the risk of hypersensitivity reactions and are suitable for patients sensitive to preservatives.

How does manufacturing complexity impact the pricing?
Complex sterilization and packaging processes increase operational costs, resulting in higher end-user prices.

Which regulatory considerations are critical?
Ensuring sterility, stability, and safety through rigorous testing and adherence to FDA guidelines.

Are there notable patent expirations influencing the market?
Existing patents on certain formulations or delivery systems influence timing for generics and biosimilars.

What regions are expected to drive future growth?
North America and Europe, where safety concerns and regulatory support for preservative-free medications are most prominent.

---

References:

[1] MarketWatch. (2023). Antihistamines Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2021). Guidance for Industry – Preservative-Free Parenteral Drugs.